| Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference |
CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2025 RBC Capital Markets Healthcare Conference on Tuesday, May 20, 2025, at 8:00 a.m. ET in New York. |
globenewswire.com |
2025-05-13 12:00:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results |
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and reported financial results for the first quarter 2025. |
globenewswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy |
Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 Phase 2 biomarker trial in FECD patients anticipated to begin in the second half of 2025 |
globenewswire.com |
2025-05-01 12:00:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 |
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients. |
globenewswire.com |
2025-04-21 20:01:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer |
CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. |
globenewswire.com |
2025-04-17 12:00:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics (DSGN) Upgraded to Buy: Here's Why |
Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-12 15:01:03 |
Czytaj oryginał (ang.) |
| Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results |
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 |
globenewswire.com |
2025-03-10 09:07:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics to Participate in Leerink's Global Healthcare Conference |
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink's Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami. |
globenewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics to Participate in Multiple Upcoming Investor Conferences |
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: |
globenewswire.com |
2024-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio |
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced its third quarter 2024 financial results and reviewed anticipated upcoming program milestones for its portfolio of GeneTAC™ candidates. |
globenewswire.com |
2024-11-07 18:01:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet |
The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-08-21 14:55:55 |
Czytaj oryginał (ang.) |
| Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio |
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials |
globenewswire.com |
2024-08-05 12:00:00 |
Czytaj oryginał (ang.) |
| The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains |
Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. |
investorplace.com |
2024-05-23 00:50:47 |
Czytaj oryginał (ang.) |
| Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones |
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTAC TM Pipeline Programs in Huntington's Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLSBAD, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced first quarter 2024 financial results along with recent business highlights and upcoming milestones. |
globenewswire.com |
2024-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference |
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. |
globenewswire.com |
2024-05-07 10:30:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript |
Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-19 22:44:02 |
Czytaj oryginał (ang.) |
| Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results |
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 |
globenewswire.com |
2024-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update |
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. |
globenewswire.com |
2024-03-12 08:30:00 |
Czytaj oryginał (ang.) |
| Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know |
Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2023-12-18 15:32:15 |
Czytaj oryginał (ang.) |
| Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 |
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results. |
globenewswire.com |
2023-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN |
NEW YORK , Oct. 9, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised to contact Robert S. |
prnewswire.com |
2023-10-09 23:02:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN |
NEW YORK , Sept. 29, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). |
prnewswire.com |
2023-09-29 22:54:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN |
NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). |
prnewswire.com |
2023-09-21 23:56:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN |
NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). |
prnewswire.com |
2023-09-13 23:20:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN |
NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). |
prnewswire.com |
2023-09-05 23:14:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN |
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised to contact Robert S. |
prnewswire.com |
2023-08-28 22:11:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN |
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ("Design" or the "Company") (NASDAQ: DSGN). Such investors are advised to contact Robert S. |
prnewswire.com |
2023-08-19 00:15:00 |
Czytaj oryginał (ang.) |
| Why Shares of Design Therapeutics Are Plummeting on Tuesday |
Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026. |
fool.com |
2023-08-15 19:02:00 |
Czytaj oryginał (ang.) |